Related Experiment Videos
Developments in glucocorticoid therapy
Johannes W J Bijlsma1, Kenneth G Saag, Frank Buttgereit
1Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Box 85500, 3508 GA Utrecht, The Netherlands. j.w.j.bijlsma@azu.nl
Abstract:
Recent evidence for a disease-modifying potential of low-dose glucocorticoids (GCs) in the treatment of rheumatoid arthritis has renewed the debate on the risk benefit ratio with this therapy. Two recent developments are described that might have a positive influence on these risk benefit ratios. One is the improvement in new GC compounds--designer GCs, alterations in bioactivity, and alterations in formulations. The other is a better understanding and management of the toxicity of GCs.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Cushing Syndrome II: Pathophysiology
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Cushing Syndrome I: Introduction
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...